Die Inhalte stammen aus dem NEJM Journal Watch Oncology & Hematology, der von der NEJM Group, a Division of the Massachusetts Medical Society, hergestellt und veröffentlich wird. Alle Rechte sind vorbehalten und alle Inhalte sind urheberrechtlich geschützt. Universimed und unsere Sponsoren ermöglichen Ihnen den Zugang zu diesen Inhalten als professionelle Unterstützung.
Pembrolizumab plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer
Combining the anti–PD-1 agent pembrolizumab with first-line chemotherapy significantly improved overall survival.
Capivasertib for Advanced ER+/HER2− Breast Cancer
Adding the investigational AKT inhibitor capivasertib to fulvestrant improved progression-free survival overall and in patients with AKT pathway alterations.
Extending Aromatase Inhibitor Therapy: Uncertainty Remains
In postmenopausal women with breast cancer, continuing anastrozole therapy for an additional 5 years improved disease-free survival.
Encouraging Results for Personalized Vaccine plus Checkpoint Inhibitor in Pancreatic Cancer
In 8 of 16 people with pancreatic cancer, a personalized mRNA vaccine plus chemotherapy eradicated the primary tumor.
Outcomes When Cabozantinib Is Added to Ipilimumab/Nivolumab in Advanced Renal Cell Carcinoma
Adding cabozantinib led to only modest improvement in progression-free survival among previously untreated patients.
Incidental Findings on Low-Dose CT for Lung Cancer Screening
Potentially clinically significant incidental findings were common, especially people with positive lung cancer screening results.
Panitumumab vs. Bevacizumab Added to Standard First-Line Chemotherapy
A new randomized trial compares these agents for patients with left-sided, RAS wild-type metastatic colorectal cancer.
Bevacizumab Added to FTD-TPI in Third-Line Therapy for Metastatic Colorectal Cancer
A phase 3, randomized, placebo-controlled trial shows benefits, including in overall survival and progression-free survival.
Breast-Conserving Therapy in Patients with Multiple Lesions
Lumpectomy followed by whole breast radiation therapy seems safe in women with multiple ipsilateral breast cancers.